German study shows clinical benefit of Nevisense
STOCKHOLM, SWEDEN, — April 29, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study published this week in Germany demonstrated the clinical benefits of Nevisense in day-to-day practice. The study titled – “Electrical Impedance Spectroscopy Improves Skin Cancer Detection and Reduces the Number of Biopsies” and authored by Dr Liebich et al was published online in the journal Dermato.The study looked at the real-life clinical effectiveness of Electrical Impedance Spectroscopy (EIS)